Edition:
United Kingdom

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,636JPY
15 Dec 2017
Change (% chg)

¥-17 (-1.03%)
Prev Close
¥1,653
Open
¥1,646
Day's High
¥1,650
Day's Low
¥1,629
Volume
897,400
Avg. Vol
1,409,133
52-wk High
¥2,134
52-wk Low
¥1,397

Latest Key Developments (Source: Significant Developments)

Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD
Wednesday, 6 Dec 2017 

Dec 5 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>::SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD.SUNOVION EXPECTS LONHALA MAGNAIR TO BE AVAILABLE IN U.S. PHARMACIES IN EARLY 2018.SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD.  Full Article

Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co .Under the terms of the agreement, Sunovion Pharmaceuticals Europe Ltd., a subsidiary company of Sumitomo Dainippon Pharma Group, has granted Angelini exclusive commercialization rights for LATUDA in 29 European countries and in Turkey.  Full Article

Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin
Monday, 30 Oct 2017 

Oct 30 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries.Under the Agreement, Poxel SA is entitled to receive an upfront payment of approximately 4.75 billion yen and future potential development milestone payments of up to 2.75 billion yen .  Full Article

Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia
Monday, 30 Oct 2017 

Oct 30 (Reuters) - POXEL SA ::SUMITOMO DAINIPPON PHARMA AND POXEL ANNOUNCE STRATEGIC PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN, CHINA AND ELEVEN OTHER ASIAN COUNTRIES.‍POXEL AND SUMITOMO DAINIPPON PHARMA TO JOINTLY DEVELOP IMEGLIMIN FOR TREATMENT OF TYPE 2 DIABETES IN JAPAN,​.‍SUMITOMO DAINIPPON PHARMA ASSUMES PHASE 3 AND COMMERCIALIZATION COSTS​.‍POXEL RECEIVES AN UPFRONT PAYMENT OF ¥4.75 BILLION (APPROXIMATELY EUR 36 MILLION, $42 MILLION)​.‍SUMITOMO DAINIPPON PHARMA SOLELY RESPONSIBLE FOR IMEGLIMIN IN CHINA, SOUTH KOREA, TAIWAN AND 9 OTHER SOUTHEAST ASIAN COUNTRIES​.‍PHASE 3 PROGRAM FOR IMEGLIMIN IN JAPAN ON TRACK TO BE INITIATED IN Q4 OF CY 2017​.‍RECEIVES FUTURE POTENTIAL DEVELOPMENT MILESTONE PAYMENTS AND SALES-BASED PAYMENTS OF UP TO ¥29.25 BILLION​.  Full Article

Kitasato Institute and Sumitomo Dainippon Pharma signs joint drug discovery research agreement
Tuesday, 24 Oct 2017 

Oct 24 (Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says it and the Kitasato Institute have signed a joint drug discovery research agreement for infections caused by bacteria with antimicrobial resistance (AMR).  Full Article

Sumitomo Dainippon Pharma unit receives Complete Response Letter from FDA for SUN-101/eFlow® New Drug Application for chronic obstructive pulmonary disease
Monday, 29 May 2017 

May 29(Reuters) - Sumitomo Dainippon Pharma Co Ltd <4506.T>:Says its US-based unit Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for SUN-101/eFlow®(glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD),including chronic bronchitis and/or emphysema, on May 26 (US Eastern time).Says the CRL does not require unit to conduct any additional clinical studies for the approval of SUN-101/eFlow®.  Full Article

Sumitomo Dainippon Pharma unit to buy 100 pct stake in Cynapsus Therapeutics Inc. at $624 mln
Tuesday, 4 Oct 2016 

Sumitomo Dainippon Pharma <4506.T>:Says its subsidiary will buy 100 percent stake in Cynapsus Therapeutics Inc. at $624 million by the end of Dec..  Full Article

Ignore Sumitomo Dainippon Pharma alert, BRIEF
Tuesday, 4 Oct 2016 

Please ignore an alert and BRIEF on Sumitomo Dainippon Pharma Co <4506.T> and Cynapsus Therapeutics Inc , which were based on a Sept. 1 news release reposted by Sumitomo Dainippon's parent company. The original story was issued on Sept. 1. [nL3N1BC57T] STORY_NUMBER:.  Full Article

Cynapsus says Sunovion Pharma entitled to termination fee of $24 mln if deal terminated - SEC filing
Thursday, 1 Sep 2016 

Cynapsus Therapeutics : Sunovion Pharma entitled to termination fee in amount of $24 million which shall be paid by co if deal terminated - SEC filing Source: (http://bit.ly/2bT5Y0k ) Further company coverage: [CTH.TO] ((Bangalore.newsroom@thomsonreuters.com;)).  Full Article

Sumitomo Dainippon Pharma to offer early-retirement program
Tuesday, 30 Aug 2016 

Sumitomo Dainippon Pharma Co Ltd <4506.T>: Says it to offer an early-retirement program to employees, who are above 45 years old as of Nov. 30 and worked more than five years (except part of employees) . Says offering period from Sep. 26 to Oct. 14 . Says the employees who take up the offer will retire on Nov. 30 .Says a premium will be added to the normal retirement payment, and the company will provide re-employment support to the retiring employees.  Full Article